EUVIMEDEUVIMED entdecken
Crossref

68 Ga ‐ FAPI ‐46 PET / CT Versus 18 F ‐ FDG PET / CT for Pancreatic Cancer: A Feasibility Study

Nicola Evans, Ebony Perkins, Sepinoud Firouzmand, Tiffany Black, Yvette Coulon, David Cavallucci, Nicholas O'Rourke iD, David Wong iD

Journal of Medical Imaging and Radiation Oncology · 25.05.2026

DOI: 10.1111/1754-9485.70124 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Imaging and Radiation Oncology, online erschienen am 25.05.2026. Verfasst von Nicola Evans und 7 weiteren Autor:innen. Beteiligte Einrichtung: I-MED Radiology Network, Brisbane, Queensland, Australia. Die Arbeit nennt 12 Literaturangaben. Gefördert von: This work supported by Wesley Research Institute..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate the feasibility of 68 Ga‐FAPI PET/CT in pancreatic cancer by comparing radiotracer uptake, lesion detection, and diagnostic value with 18 F‐FDG PET/CT.

Methods

Ten participants (seven male, three female; mean age 68 years) with suspected or confirmed pancreatic cancer underwent both 68 Ga‐FAPI and 18 F‐FDG PET/CT. Imaging was assessed for uptake, lesion detection, and diagnostic usefulness as determined by clinicians.

Results

Ten participants (seven male, three female; mean age 68 years) underwent imaging. Mean SUVmax of the primary lesion was higher for 68 Ga‐FAPI compared with 18 F‐FDG in participants with an identifiable primary lesion ( n = 9) (13.8 [range 6.2–19.6] vs. 7.0 [range 0.0–12.5]). 68 Ga‐FAPI identified additional lesions in three participants, resulting in imaging‐based upstaging in three cases. Clinicians considered FAPI more diagnostically useful in five participants and equivalent in the remainder, based on comparison of lesion detection, delineation, and staging impact. Increased uptake was also seen in areas of presumed inflammation. No adverse events were reported.

Conclusions

This feasibility study shows that 68 Ga‐FAPI PET/CT is safe, demonstrates higher uptake than FDG, and can reveal additional lesions that influence staging. Imaging‐based upstaging was observed in three participants, supporting further investigation of FAPI as a complementary tool in pancreatic cancer imaging. Larger prospective studies are needed to determine the clinical impact of 68 Ga‐FAPI PET/CT in pancreatic cancer.

Schlagwörter

Stichwörter der Autor:innen

68Ga‐FAPI‐46FDG PET/CTfibroblast activation protein inhibitor (FAPI)molecular imagingpancreatic cancerstaging and re‐staging

Autor:innen und Institutionen

  • I-MED Radiology Network, Brisbane, Queensland, Australia.
  • The Wesley Hospital, Brisbane, Queensland, Australia.
  • Wesley Research Institute, The Wesley Hospital, Brisbane, Australia.

ORCID-Profile: Nicholas O'Rourke, David Wong

Förderung

  • This work supported by Wesley Research Institute.

Zitieren

APA

Evans, N., Perkins, E., Firouzmand, S., Black, T., Coulon, Y., Cavallucci, D., O'Rourke, N., & Wong, D. (2026). 68 Ga ‐ FAPI ‐46 PET / CT Versus 18 F ‐ FDG PET / CT for Pancreatic Cancer: A Feasibility Study. Journal of Medical Imaging and Radiation Oncology. https://doi.org/10.1111/1754-9485.70124

Vancouver

Evans N, Perkins E, Firouzmand S, Black T, Coulon Y, Cavallucci D, et al. 68 Ga ‐ FAPI ‐46 PET / CT Versus 18 F ‐ FDG PET / CT for Pancreatic Cancer: A Feasibility Study. Journal of Medical Imaging and Radiation Oncology. 2026. doi:10.1111/1754-9485.70124

BibTeX
@article{Evans2026,
  author = {Evans, Nicola and Perkins, Ebony and Firouzmand, Sepinoud and Black, Tiffany and Coulon, Yvette and Cavallucci, David and O'Rourke, Nicholas and Wong, David},
  title = {68 Ga ‐ FAPI ‐46 PET / CT Versus 18 F ‐ FDG PET / CT for Pancreatic Cancer: A Feasibility Study},
  journal = {Journal of Medical Imaging and Radiation Oncology},
  year = {2026},
  doi = {10.1111/1754-9485.70124}
}
Kostenlos starten →